AdaptHealth Corp 8-K, filed Dec 13, 2024
AdaptHealth Corp. (AHCO)
About this 8-K
AdaptHealth Corp filed this 8-K on December 13, 2024, reporting on events of December 9, 2024.
Items reported
- Item 5.02: Director or officer change, or executive pay
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 OR 15(d)
of The Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
| (State
or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
| (Address of principal executive offices) | (Zip Code) | |
| ( |
||
(Registrant’s telephone number, including area code) |
||
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Amendment to Rietkerk Transition, Separation and Release Agreement
On December 9, 2024, AdaptHealth Corp. (the “Company”) entered into an amendment (the “Rietkerk Amendment”) to its transition, separation, and release agreement with Shaw Rietkerk, the Company’s Chief Business Officer, dated August 21, 2024, pursuant to which Mr. Rietkerk agreed to reduce his annual base salary from $500,000 to $125,000 commencing on January 1, 2025. The foregoing description of the Rietkerk Amendment is qualified in its entirety by reference to the full text of the Rietkerk Amendment, which is attached as Exhibit 10.1 hereto and incorporated by reference herein.
Item 9.01 Financial Statements and Exhibits.
| (d) | Exhibits |
| Exhibit No. | Description |
| 10.1 | Amendment to Transition, Separation and Release Agreement between AdaptHealth Corp. and Shaw Rietkerk, dated December 9, 2024. |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
- 2 -
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
Dated: December 13, 2024
| AdaptHealth Corp. | |||
| By: | /s/ Jason Clemens | ||
| Name: | Jason Clemens | ||
| Title: | Chief Financial Officer | ||
- 3 -
Exhibit 10.1
Amendment to Transition, Separation, and Release Agreement
This amendment, delivered on December 9, 2024, confirms the following understandings and agreements between AdaptHealth Corp. (the “Company”) and Shaw Rietkerk (hereinafter referred to as “you” or “your”).
WHEAREAS, the parties entered a “Transition and Separation Agreement” on August 21, 2024, and have agreed to amend section 2. (a) of that agreement to change the annual base pay that you will be paid from January 1, 2025, until the Separation Date (March 31, 2025) to $125,000 per annum. The Company and you agree that all other terms in the “Transition and Separation Agreement” will remain the same.
IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date set forth below.
| ADAPTHEALTH CORP. | ||
| By: | /s/ Suzanne Foster | |
| Name: | Suzanne Foster | |
| Title: | Chief Executive Officer | |
| SHAW RIETKERK | ||
| /s/ Shaw Rietkerk | ||
| SHAW RIETKERK | ||
| Dated: December 9, 2024 | ||